Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Genitourinary, Gastrointestinal, Breast, and Lung Cancers: CCO Independent Conference Highlights of the 2021 Virtual ESMO Annual Meeting
  • CME

Eva M. Ciruelos, MD, PhD
Karim Fizazi, MD, PhD
Eric Van Cutsem, MD, PhD
person default
Vamsidhar Velcheti, MD
Released: December 15, 2021
Back Next

References

  1. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
  2. Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract 576MO.
  3. Fizazi K, Maldonado X, Foulon S, et al. A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): first results of PEACE-1. Presented at: 57th Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 5000.
  4. Fizazi K, Carles J, Foulon GS, et al. A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. Presented at: European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA5_PR.
  5. Attard G, Brown LC, Clarke N, et al. Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): combined analysis from two comparisons in the STAMPEDE platform protocol. Presented at: European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA4_PR.
  6. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
  7. Fizazi K, Carmel A, Joly F, et al. Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. Presented at: European Society for Medical Oncology Congress; October 19-23, 2018. Abstract 791O.
  8. James N, Ingleby F, Clarke N, et al. Docetaxel for hormone-naive prostate cancer (PCa): results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial. Presented at: European Society for Medical Oncology Congress; September 27-October 1, 2019. Abstract 855PD.
  9. Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686-700.
  10. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163-1177.
  11. Agarwal N, McGregor BA, Maughan BL, et al. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results of expanded cohort 6 of the COSMIC-021 study. Presented at: European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA24.
  12. Smith M, De Bono J, Sternberg C, et al. Phase III Study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34:3005-3013.
  13. Kwilas AR, Ardiani A, Donahue RN, et al. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12:294.
  14. Agarwal N, Loriot Y, McGregor, BA, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results of cohort 6 of the COSMIC-021 study. Presented at: 56th Annual Meeting of the American Society of Clinical Oncology; May 29-31, 2020. Abstract 5564.
  15. ClinicalTrials.gov. Study of cabozantinib in combination with atezolizumab versus second NHT in subjects with mCRPC (CONTACT-02). clinicaltrials.gov/ct2/show/NCT04446117. Accessed December 5, 2021.
  16. Van Cutsem E, Di Bartolomeo M, Smyth E, et al. Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA55.
  17. Trastuzumab deruxtecan [prescribing information]. Cambridge, United Kingdom: AstraZeneca; 2019.
  18. Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419-2430.
  19. ClinicalTrials.gov. Trastuzumab deruxtecan for subjects with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen (DESTINY-Gastric04). clinicaltrials.gov/ct2/show/NCT04704934. Accessed December 5, 2021.
  20. Cascinu S, Bodoky G, Muro K, et al. Tumor response and symptom palliation from RAINBOW, a Phase III trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer. Oncologist. 2021;26:e414.
  21. Janjigian YY, Ajani JA, Moehler M, et al. Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA7.
  22. Moehler M, Shitara K, Garrido M, et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Presented at: 2020 European Society for Medical Oncology Virtual Congress; September 19- October 18, 2020. Abstract LBA6.
  23. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40.
  24. Chau I, Yuichiro D, Jaffer A, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. J Clin Oncol. 2021;39:15.
  25. Klempner S, Keun-Wook L, Metges J, et al. Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2. J Clin Oncol. 2021;39:15.
  26. Merz V, Zecchetto C, Simionato F, et al. A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Ther Adv Med Oncol. 2020;12:1758835920937889.
  27. Mulcahy MF, Salem R, Mahvash A, et al. Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial (EPOCH study). Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA21.
  28. Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021;[Epub ahead of print].
  29. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687-3694.
  30. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18:1159-1171.
  31. Weiss J, Yaeger RD, Johnson ML, et al. KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA6.
  32. Cortés J, Kim S, Chung W, et al. LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA1.
  33. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.
  34. Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21:1283-1295.
  35. Aoki M, Iwasa S, Boku N. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer. 2021;24:567-576.
  36. Modi S, Saura C, Yamashita T, et al. Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer. Presented at: 2020 San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD3-06.
  37. Saura Manich C, O’Shaughnessy J, Aftimos PG, et al. Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA15.
  38. Van der Lee MMC, Groothuis PG, Ubink R, et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther. 2015;14:692-703.
  39. Cortés J, Cescon DW, Rugo HS, et al. KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA16.
  40. Cortés J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817-1828.
  41. Pembrolizumab [prescribing information]. Readington Township, NJ: Merck; 2021.
  42. Pallai RN, Behera, M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: a report from the lung cancer mutation consortium. Cancer. 2017;123:4099-4015.
  43. Li BT, Smit EFF, Goto Y, et al. Primary data from DESTINY-Lung01: a phase II trial of trastuzumab deruxtecan (T-Dxd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC). Presented at: European Society for Medical Oncology Congress 2021; September 16-21 2021. Abstract LBA45.
  44. Li, BT, Smit, EF, Goto, Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2021;[Epub ahead of prnt].
  45. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide verses platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-1939.
  46. Durvalumab [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2021.
  47. Goldman JW, Dvorkin, M, Chen Y, et al. Durvaluab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51-65.
  48. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from phase III CASPIAN study. Presented at: European Society for Medical Oncology Congress 2021; September 16-21 2021. Abstract LBA61.
  49. Mito R, Matsubara E, Komohara Y, et al. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int. 2020;70:287-294.
  50. Okajima D, Yasuda, S, Maejima, T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;[Epub ahead of print].
  51. Spira A, Lisberg AE, Sands JM, et al. Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ASC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA03.03.
  52. Garon EB, Jonson ML, Lisberg AE, et al. Efficacy of datopotamab deruxtecan (Dato-Dxd) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase 1 TROPION-PanTumor01 study. Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract LBA49.
  53. Garon EB, Johnson M, Lisberg AE, et al. TROPION-PanTumor01: updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. Presented at: 23rd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; September 8-14, 2021. Abstract MA03.02.
  54. ClinicalTrials.gov. Study of DS-1062a in advanced or metastatic non-small cell lung cancer with actionable genomic alterations (TROPION-Lung05). clinicaltrials.gov/ct2/show/NCT04484142. Accessed December 5, 2021.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings